Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03343067 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain
A Phase 3 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT03343067 is a Phase 3 study that was terminated before completion, run by AbbVie. The registered enrollment target is 11 participants.
The verdict
NCT03343067, a Phase 3 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a Phase 3, dose-escalation study designed to evaluate the safety and efficacy of both elagolix alone and elagolix plus estradiol/norethindrone acetate (E2/NETA) over 24 months in the management of endometriosis with associated moderate to severe pain in premenopausal women.
Interventions
- DRUG elagolix
- DRUG estradiol/norethindrone acetate (E2/NETA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-12-27 |
| Est. Completion | 2018-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03343067
The ClinicalTrials.gov registry entry for NCT03343067 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which elagolix is the first listed.
NCT03343067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03343067 about?
NCT03343067 is a clinical study titled "A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain". This is a Phase 3, dose-escalation study designed to evaluate the safety and efficacy of both elagolix alone and elagolix plus estradiol/norethindrone acetate (E2/NETA) over 24 months in the management of endometriosis with associated moderate to severe pain in premenopausal women.
What is the current status of trial NCT03343067?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2017-12-27. Estimated completion is 2018-10-23.
What interventions are being tested in trial NCT03343067?
The interventions under investigation include: elagolix (DRUG), estradiol/norethindrone acetate (E2/NETA) (DRUG).
Who is sponsoring clinical trial NCT03343067?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.